Lazard Asset Management’s Grandstand Limited Ordinary Shares GRSD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-10,776
Closed -$88.1K 1940
2025
Q3
$88.1K Sell
10,776
-26,530
-71% -$257K ﹤0.01% 1700
2025
Q2
$443K Sell
37,306
-48,292
-56% -$595K ﹤0.01% 1522
2025
Q1
$1.08M Buy
85,598
+12,474
+17% +$175K ﹤0.01% 1189
2024
Q4
$1.03M Buy
73,124
+27,844
+61% +$327K ﹤0.01% 1141
2024
Q3
$453K Buy
45,280
+17,664
+64% +$167K ﹤0.01% 1385
2024
Q2
$227K Buy
27,616
+14,668
+113% +$124K ﹤0.01% 1516
2024
Q1
$118K Sell
12,948
-603
-4% -$5.47K ﹤0.01% 1478
2023
Q4
$132K Buy
13,551
+277
+2% +$3.22K ﹤0.01% 1545
2023
Q3
$173K Buy
13,274
+3,235
+32% +$41K ﹤0.01% 1438
2023
Q2
$102K Hold
10,039
﹤0.01% 1569
2023
Q1
$99K Buy
10,039
+3,811
+61% +$36.6K ﹤0.01% 1536
2022
Q4
$56K Buy
+6,228
New +$53.9K ﹤0.01% 1749
2021
Q4
Sell
-1,042
Closed -$9K 2345
2021
Q3
$9K Buy
+1,042
New +$9.09K ﹤0.01% 2076

Other funds holding GRSD

Lazard Asset Management's GRSD Position: Q4 2025 in Review

Lazard Asset Management sold out of Grandstand Limited Ordinary Shares (GRSD) in Q4 2025, closing a stake of 10,776 shares — an estimated $88.1K sold.

Lazard Asset Management first reported a position in GRSD in Q3 2021 and held it in 13 quarters. The position peaked at $1.08M in Q1 2025. 117 funds tracked by Wall St. Rank hold GRSD as of Q4 2025.

  • Lazard Asset Management reported no remaining Grandstand Limited Ordinary Shares position as of Q4 2025 after selling out during the quarter.
  • Lazard Asset Management sold 10,776 Grandstand Limited Ordinary Shares shares in Q4 2025, an estimated $88.1K.
  • Lazard Asset Management first reported a position in Grandstand Limited Ordinary Shares in Q3 2021 and held it in 13 quarters.
  • Lazard Asset Management's Grandstand Limited Ordinary Shares position peaked at $1.08M in Q1 2025.
  • 117 funds tracked by Wall St. Rank held Grandstand Limited Ordinary Shares as of Q4 2025.

Based on Lazard Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.